- Home
- CRIS vs IOBT Comparison
CRIS vs IOBT Comparison
Compare CRIS & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRIS | IOBT |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0M | 12.7M |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CRIS | IOBT |
|---|---|---|
| Price | $0.58 | $0.04 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 4 |
| Target Price | ★ $17.00 | $2.25 |
| AVG Volume (30 Days) | 657.5K | ★ 186.6M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.57 | 26.77 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,898,000.00 | N/A |
| Revenue This Year | $27.10 | N/A |
| Revenue Next Year | $67.74 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 31.50 | N/A |
| 52 Week Low | $0.49 | $0.03 |
| 52 Week High | $3.13 | $2.79 |
Technical Indicators
Market Signals| Indicator | CRIS | IOBT |
|---|---|---|
| Relative Strength Index (RSI) | 43.75 | 25.94 |
| Support Level | $0.51 | N/A |
| Resistance Level | $0.79 | $0.22 |
| Average True Range (ATR) | 0.05 | 0.02 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 43.91 | 15.92 |
Price Performance
Historical ComparisonAbout CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.